Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 64, Issue 1, 2009, Pages 158-165

  Bachert, C ^a   Kuna, P ^b   Sanquer, F ^c   Ivan, P ^d   Dimitrov, V ^e   Gorina, M M ^f   Van De Heyning, P ^g   Loureiro, A ^h  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c Cabinet d'Allergologie et Immunologie Clinique   (France)

^d Emergency Clinical Hospital 'Sf Spiridon'   (Romania)

^e Alexandrosvska MHAT Hospital   (Bulgaria)

^f Hospital Cruz Roja   (Spain)

^g ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^h CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Bilastine; Desloratadine; H1 antihistamine; Quality of life; Seasonal allergic rhinitis; Total symptom score

Indexed keywords

ANTIHISTAMINIC AGENT; BILASTINE; DESLORATADINE; PLACEBO; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EAR; ELECTROCARDIOGRAM; EPIPHORA; FATIGUE; FEMALE; HEADACHE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NASAL PRURITUS; NOSE OBSTRUCTION; OCULAR PRURITUS; PALATE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; SNEEZING; SOMNOLENCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 58149139387     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2008.01813.x     Document Type: Article

References (34)

1. Bousquet J, Van CP, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 108 (Suppl. 5 S147 S334.
2. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004 24 : 758 764.
3. Bachert C, van Cauwenberge P, Olbrecht J, van Schoor J. Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium. Allergy 2006 61 : 693 698.
4. Task Force on Allergic Disorders. The Allergy Report. American Academy of Allergy Asthma and Immunology http://www.aaaai.org/professionals.stm (accessed January 2007).
5. van Hoecke, Vastesaeger N, Dewulf L, Sys L, Van Cauwenberge P. Classification and management of allergic rhinitis patients in general practice during pollen season. Allergy 2006 61 : 705 711.
6. Schoenwetter WF, Dupclay L, Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality of life burden of allergic rhinitis. Curr Med Res Opin 2004 20 : 305 317.
7. Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis. Pharmacoeconomics 2004 22 : 345 361.
8. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001 108 (Suppl. 1 S2 S8.
9. Weir E. The burden of rhinitis: nothing to sniff at. CMAJ 2003 169 : 694.
10. Demoly P, Bencherioua AM, Crampette L, Dhivert-Donnadieu H, Godard P, Michel FB. From allergic rhinitis to sinus diseases (sinusitis/nasal polyps): epidemiologic and experimental links. Rev Mal Respir 2000 17 : 925 930.
11. Skoner DP. Complications of allergic rhinitis. J Allergy Clin Immunol 2000 105 : S605 S609.
12. Rachelefsky GS. National guidelines needed to manage rhinitis and prevent complications. Ann Allergy Asthma Immunol 1999 82 : 296 305.
13. Bachert C. The role of histamine in allergic disease: re-appraisal of its inflammatory potential. Allergy 2002 57 : 287 296.
14. Plaut M, Valentine MD. Clinical practice. Allergic rhinitis. N Engl J Med 2005 353 : 1934 1944.
15. Gelfand EW, Plaut M, Washington T. Current trends in allergic reactions: a multidisciplinary approach to patient management. Interdisciplinary Med 2003 5 : 1 12.
16. van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW, Durham SR et al. Consensus statement on the treatment of allergic rhinitis. Allergy 2000 55 : 116 134.
17. 1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005 6 : 371 384.
18. Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs R D 2006 7 : 219 231.
19. Sologuren A, Valiente R, Crean C, McLaverty A. Relationship of dose to inhibition of wheal and flare for 5 doses of bilastine and 10 mg cetirizine. J Clin Pharmacol 2007 47 (9 1198 (abstract 69).
20. Lucero ML, Orjales A, Morag N. In vitro hepatic metabolism of [14C] bilastine. Drug Metabol Rev 2007 39 (Suppl. 1 114 (abstract 160).
21. FAES FARMA S.A. Bilastine, Investigational Drug Brochure version 8.0, July 2007. FAES FARMA S.A. http://www.faes.es.
22. Garcia-Gea C, Clos S, Antinijoan RM, Gich I, Valiente R, Barbanoj MJ. Crossover, randomised, double-blind, double-dummy, placebo and positive standard-controlled trial to assess the possible interaction on CNS effects between bilastine 20 mg and 80 mg) and alcohol (0.8 g/kg) after single simultaneous administration in healthy subjects. Pharmacol Toxicol 2006 99 (Suppl. 1 30. (abstract).
23. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991 21 : 77 83.
24. Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Inmmunol 1997 9 : S742 S749.
25. Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000 30 : 891 899.
26. Crean C, Roupe K, Sologuren A, Valiente R. The pharmacokinetics of bilastine after single and 14 days once daily administration. Basin Clin Pharmacol Toxicol 2007 101 (Suppl. 1 148.
27. Sologuren A, Valiente R, Allison M, Tyl B. Lack of significant effect of bilastine on ventricular repolarization. A thorough QT/QTc study. Allergy 2008 63 (Suppl. 88 85 (abstract 189).
28. Meltzer EO, Prenner BM, Nayak A. Efficacy and tolerability of once-daily 5mg desloratadine, an H1 antagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy seasons. Clin Drug Invest 2001 104 (Suppl. 1 383 384.
29. Bachert C, Virchow JC, Plencker A. Desloratadine in the treatment of seasonal allergic rhinitis: results of a large observational study. Clin Drug Invest 2002 22 (Suppl. 2 43 52.
30. Lehman JM, Blaiss MS. Selecting the optimal oral antihistamine for patients with allergic rhinitis. Drugs 2006 66 : 2309 2319.
31. Golightly LK, Greos LS. Second-generation antihistamines. Actions and efficacy in the management of allergic disorders. Drugs 2006 65 : 341 384.
32. Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundamental Clin Pharmacol 2004 18 : 399 411.
33. Henz BM. The pharmacological profile of desloratadine: a review. Allergy 2001 56 : 7 13.
34. Kuna P, Nowacki Z, van Cauwenberghe P, Lukat K, Spicakova M, Agache I et al. A phase 3 study comparing the efficacy and safety of once daily bilastine with cetirizine and placebo for the treatment of seasonal allergic rhinitis. Allergy 2007 62 (Suppl. 83 132 (abstract).